SCHEMBL28640716

SCHEMBL28640716

CC(C)(C)OC(=O)N1CCC(n2ccc(=O)[nH]c2=O)CC1

nearest known ligand 0.58

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
HCAR1 Q9BXC0 1/20 0.58
KDM4E B2RXH2 2/20 0.54
MAPT P10636 2/20 0.54
THRB P10828 1/20 0.54
PRKCG P05129 1/20 0.47
PRKCB P05771 1/20 0.47
PRKCA P17252 1/20 0.47
PRKCH P24723 1/20 0.47
PRKCE Q02156 1/20 0.47
PRKCD Q05655 1/20 0.47
GPR119 Q8TDV5 5/20 0.46
PTPN2 P17706 1/20 0.45
PTPN1 P18031 1/20 0.45
PTPN6 P29350 1/20 0.45
TP53 P04637 1/20 0.45
FPR2 P25090 1/20 0.44
ALDH1A1 P00352 2/20 0.44
CTSD P07339 1/20 0.43
CTSE P14091 1/20 0.43
BACE1 P56817 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL13968 0.93 HCAR1 (0.51) HCAR1KDM4EMAPTTHRBPRKCG
SCHEMBL30087102 0.93 HCAR1 (0.51) HCAR1KDM4EMAPTTHRBPRKCG
SCHEMBL2604302 0.82 MAPT (0.50) HCAR1KDM4EMAPTTHRBPRKCG
SCHEMBL28397415 0.81 KDM4E (0.52) HCAR1KDM4EMAPTTHRBGPR119
SCHEMBL22119700 0.80 SLC28A1 (0.39) HCAR1DDB1CRBN
SCHEMBL3248282 0.79 HCAR1 (0.49) HCAR1KDM4EMAPTTHRBPRKCG
SCHEMBL31451173 0.79 KDM4E (0.45) HCAR1KDM4EMAPTTHRBGPR119
SCHEMBL30087083 0.79 KDM4E (0.53) HCAR1KDM4EMAPTTHRBGPR119
SCHEMBL3243873 0.78 HCAR1 (0.48) HCAR1KDM4EMAPTTHRBPRKCG
SCHEMBL14334645 0.78 GPR119 (0.59) HCAR1KDM4EMAPTTHRBPRKCG

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20260015338-A1 TARGETED PROTEIN DEGRADATION C4 THERAPEUTICS, INC. (US) 2026-01-15 US disclosed
US-12454521-B2 Targeted protein degradation C4 THERAPEUTICS, INC. 2025-10-28 US disclosed
US-20220372016-A1 TARGETED PROTEIN DEGRADATION C4 THERAPEUTICS, INC. (US) 2022-11-24 US disclosed
CN-113453679-A Targeted protein degradation C4医药公司 2021-09-28 CN disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20260015338-A1 TARGETED PROTEIN DEGRADATION PSMC3, PSMA6, ADRM1 HCAR1 1628/4885KDM4E 1157/4885MAPT 2902/4885
US-20220372016-A1 TARGETED PROTEIN DEGRADATION STUB1, MDM2, UBE3A HCAR1 3811/4885KDM4E 781/4885MAPT 288/4885
US-12454521-B2 Targeted protein degradation STUB1, MDM2, UBE3A HCAR1 3811/4885KDM4E 781/4885MAPT 288/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.